RxDoctor Payments Data

William Christensen, NP

Family · St George, UTNPI 1043450760

Payments from drug & device makers

$1,922in general payments, 2019–2025

Across 107 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$937
  • AbbVie$309
  • Boehringer Ingelheim$168
  • Lilly USA, LLC$136
  • Gilead$75
  • Indivior Inc.$65
  • plus $232 from 10 others

What the payments were for

  • Food & beverage$1,922100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,922 in reported general payments places this provider in the 80th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$11,958
Medicare patients
57
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$108,207
JardianceEmpagliflozin69$77,162
TrulicityDulaglutide59$68,264
EliquisApixaban46$43,951
Xigduo XrDapaglifloz Propaned/Metformin30$43,229
OzempicSemaglutide30$38,053
XareltoRivaroxaban21$34,569
LinzessLinaclotide29$15,948
MounjaroTirzepatide14$14,507
RybelsusSemaglutide13$12,803
TradjentaLinagliptin12$10,152
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$9,768
Levemir FlexpenInsulin Detemir30$9,045
Victoza 3-PakLiraglutide11$8,358
ShingrixVaricella-Zoster Ge/As01b/Pf35$7,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$937$108,20783 claims
Boehringer IngelheimJardiance, Tradjenta$168$87,31481 claims
Lilly USA, LLCTrulicity, Mounjaro$136$82,77173 claims
Novo NordiskOzempic, Rybelsus$44$50,85643 claims
AbbVieLinzess$309$15,94829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,460 family providers in Utah.

Other family in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →